Recent Advances in the Management of Patients with Advanced Hepatocellular Carcinoma: How Does Your Approach Compare with the Experts’?

Target Audience
This activity is intended for US-based hematologists/oncologists, hepatologists, gastroenterologists, interventional radiologists, pathologists, and other members of the multidisciplinary oncology team (NPs, PAs, pharmacists) responsible for the care of patients with HCC.

Program Overview
This case-based enduring virtual activity is designed to improve clinicians’ ability to use an evidence-based approach for the selection of therapies for the treatment of patients with advanced hepatocellular carcinoma (HCC); adopt protocols to minimize the harms attributable to the use of guideline-recommended systemic therapies; in addition to considering the biomarker status of patients with advanced HCC when developing management strategies.

Learning Objectives
Upon completion of this activity, participants should be better able to:
Evaluate evidence from clinical trials assessing emerging therapies for the treatment with advanced HCC
Devise strategies to manage the therapy-related AEs associated with guideline recommended systemic therapies for the treatment of advanced HCC
Interpret data on biomarkers that may help inform treatment decision making for patients with advanced HCC